Sequella Inks $50M Licensing Deal for Tuberculosis Drug
By Catherine Shaffer
Tuesday, April 26, 2011
Powerful multidrug cocktails are critically important for battling multidrug-resistant tuberculosis (TB). Industry is working hard to develop new drugs that will not only work well individually, but synergistically, creating an effect where the whole is more than the sum of the parts.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.